Aca­dia adopts a new PhI­II game plan for 'break­through' med, dumps Alzheimer's PhII

Aca­dia $ACAD has de­cid­ed to change the game for its drug Nu­plazid (pi­ma­vanserin) go­ing fur­ther in­to Phase III, af­ter the FDA hand­ed out its break­through drug des­ig­na­tion for the ther­a­py.

Ap­proved al­ready for Parkin­son’s dis­ease psy­chosis, the biotech had been set­ting the stage for a piv­otal tri­al in Alzheimer’s dis­ease psy­chosis for their 5-HT2A ther­a­py. But in an­nounc­ing the launch of their HAR­MO­NY study, ex­ecs say now that they will re­cruit a mix of pa­tients with Alzheimer’s dis­ease, de­men­tia with Lewy bod­ies, Parkin­son’s dis­ease de­men­tia, vas­cu­lar de­men­tia and fron­totem­po­ral de­men­tia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.